Pashamylaram Pharma blast kills 36; CM announces Rs 1 crore compensation
Advertisement
Hyderabad: In a tragic turn of events, the death toll from the explosion at Sigachi Industries Ltd's pharmaceutical plant in Pashamylaram has climbed to 36, Telangana Chief Minister Revanth Reddy confirmed during his visit to the blast site on Tuesday.
The devastating blast, which shook the industrial area, has also left several workers injured and many others missing.
CM Reddy assured that the state government will work closely with the company management to ensure a compensation of Rs 1 crore is paid to the kin of the deceased.
As per PTI, the CM also said those who are seriously injured will receive Rs 10 lakh, while those who are injured but can resume work after some recovery will be provided Rs 5 lakh.
“The state government will talk to the company management that Rs 1 crore each compensation will be paid to the deceased families. I have issued orders that from both the government side and company side Rs 1 Crore compensation will be paid,” the CM said.
Also, the state government will pay Rs 1 lakh each to the families of the deceased and Rs 50,000 to the injured to meet any immediate and emergency expenses.
According to information provided by the officials, most of the deceased were from Odisha, Bihar, Andhra Pradesh, Madhya Pradesh and Telangana.
There were 143 people at the time of the blast out of which 56 are in touch with the officials. Search is on the rest of the people.
“Thirty six people have lost their lives. Some are still missing. Officials are in the process of collecting information,” he said.
Reddy further said the medical expenses for the injured will be borne by the state government and Sigachi.
He asserted that action will be taken against those responsible for the unfortunate incident.
Later, the CM visited the injured at the hospital.
Read also: Aurobindo Pharma arm restarts production at Kakinada Penicillin-G plant after fire incident
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.